SLC25A21 Correlates with the Prognosis of Adult Acute Myeloid Leukemia Through Inhibiting the Growth of Leukemia Cells Via Downregulating CXCL8

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2024 Dec 20

PMID 39706835

Authors

Yu Liu

Yan Xu

Qianqian Hao

Luyao Shi

Yufei Chen

Yajun Liu

Mengya Li

Yu Zhang

Tao Li

Yafei Li

Zhongxing Jiang

Yanfang Liu

Chong Wang

Zhilei Bian

Lu Yang

Shujuan Wang

Affiliations

Soon will be listed here.

Abstract

In recent years, targeting mitochondrial apoptosis has emerged as a promising therapeutic strategy for Acute Myeloid Leukemia (AML). The SLC25 family of mitochondrial carriers plays a critical role in maintaining mitochondrial function and regulating apoptosis. However, the role of SLC25A21, an oxodicarboxylate carrier, in AML progression and its potential as a prognostic biomarker remain underexplored. This study aimed to further investigate the role, molecular mechanism, and potential clinical value of SLC25A21 in AML progression. The transcript levels of SLC25A21 in bone marrow specimens were analyzed using real-time quantitative polymerase chain reaction. The correlation between SLC25A21 expression and the prognosis of AML was assessed through survival analysis. Findings revealed that SLC25A21 was downregulated in adult AML, and the low expression of SLC25A21 was correlated with worse prognosis for AML patients. Furthermore, overexpression of SLC25A21 inhibited cell proliferation and cell cycle progression, and was correlated with apoptosis through mitochondrial apoptosis signaling pathway. C-X-C motif chemokine ligand 8 (CXCL8) was identified as a downstream target of SLC25A21. These functions of SLC25A21 could be rescued by the overexpression of CXCL8. Moreover, SLC25A21 overexpression significantly suppressed the growth of xenograft tumors. In conclusion, the low SLC25A21 expression is correlated with poor clinical outcome. The overexpression of SLC25A21 inhibited the AML cell survival and proliferation by dysregulating the expression of CXCL8. SLC25A21 might be a potential prognostic marker and a treatment target for AML.

References

Martinou J, Green D . Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001; 2(1):63-7. DOI: 10.1038/35048069. View

Achanta G, Sasaki R, Feng L, Carew J, Lu W, Pelicano H . Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005; 24(19):3482-92. PMC: 1276176. DOI: 10.1038/sj.emboj.7600819. View

Shi X, Zhu K, Ye Z, Yue J . VCP/p97 targets the nuclear export and degradation of p27 during G1 to S phase transition. FASEB J. 2020; 34(4):5193-5207. DOI: 10.1096/fj.201901506R. View

Ha H, Debnath B, Neamati N . Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017; 7(6):1543-1588. PMC: 5436513. DOI: 10.7150/thno.15625. View

Liu Y, Chen Y, Liu Y, Li M, Zhang Y, Shi L . Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype. J Transl Med. 2022; 20(1):612. PMC: 9783723. DOI: 10.1186/s12967-022-03831-8. View

Li J, Lian Z, Xu Y, Liu R, Wei Z, Li T . Downregulation of nuclear protein-1 induces cell cycle arrest in G0/G1 phase in glioma cells in vivo and in vitro via P27. Neoplasma. 2020; 67(4):843-850. DOI: 10.4149/neo_2020_190814N759. View

Xiao Y, Yang Z, Cheng X, Fang X, Shen T, Xia C . CXCL8, overexpressed in colorectal cancer, enhances the resistance of colorectal cancer cells to anoikis. Cancer Lett. 2015; 361(1):22-32. DOI: 10.1016/j.canlet.2015.02.021. View

Ramachandra N, Gupta M, Schwartz L, Todorova T, Shastri A, Will B . Role of IL8 in myeloid malignancies. Leuk Lymphoma. 2023; 64(11):1742-1751. DOI: 10.1080/10428194.2023.2232492. View

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

10.

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

11.

Luna-Vargas M, Chipuk J . The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane. FEBS J. 2015; 283(14):2676-89. PMC: 4907887. DOI: 10.1111/febs.13624. View

12.

Carter B, Mak D, Woessner R, Gross S, Schober W, Estrov Z . Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009; 23(10):1755-62. PMC: 3593228. DOI: 10.1038/leu.2009.101. View

13.

Chen X, Glytsou C, Zhou H, Narang S, Reyna D, Lopez A . Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discov. 2019; 9(7):890-909. PMC: 6606342. DOI: 10.1158/2159-8290.CD-19-0117. View

14.

Gao Y, Yin J, Tu Y, Chen Y . Theaflavin-3,3'-Digallate Suppresses Human Ovarian Carcinoma OVCAR-3 Cells by Regulating the Checkpoint Kinase 2 and p27 kip1 Pathways. Molecules. 2019; 24(4). PMC: 6412557. DOI: 10.3390/molecules24040673. View

15.

Cui L, Liu Y, Pang Y, Qian T, Quan L, Cheng Z . Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia. Cancer Gene Ther. 2019; 27(1-2):1-14. DOI: 10.1038/s41417-019-0119-5. View

16.

Weng J, Salazar N . DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival. Int J Mol Sci. 2021; 22(3). PMC: 7864199. DOI: 10.3390/ijms22031020. View

17.

Sasaki K, Ravandi F, Kadia T, DiNardo C, Short N, Borthakur G . De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021; 127(12):2049-2061. PMC: 11826308. DOI: 10.1002/cncr.33458. View

18.

Xia W, Chen W, Zhang Z, Wu D, Wu P, Chen Z . Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis. PLoS One. 2015; 10(4):e0123484. PMC: 4391830. DOI: 10.1371/journal.pone.0123484. View

19.

Cheng W, Leach K, Hardwick J . Mitochondrial death pathways in yeast and mammalian cells. Biochim Biophys Acta. 2008; 1783(7):1272-9. PMC: 2519237. DOI: 10.1016/j.bbamcr.2008.04.012. View

20.

Fiermonte G, Dolce V, Palmieri L, Ventura M, Runswick M, Palmieri F . Identification of the human mitochondrial oxodicarboxylate carrier. Bacterial expression, reconstitution, functional characterization, tissue distribution, and chromosomal location. J Biol Chem. 2000; 276(11):8225-30. DOI: 10.1074/jbc.M009607200. View